Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells

R. Zambello, L. Trentin, C. Feruglio, P. Bulian, M. Masciarelli, A. Cipriani, C. Agostini, G. Semenzato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this study we addressed the question of whether lymphokine-activated killer (LAK) cells, besides killing neoplastic cells, may exert a certain degree of lysis on the normal counterpart; in particular we took into consideration the toxicity against pulmonary alveolar macrophages (PAM). We demonstrated that human LAK cells generated in vitro following incubation of peripheral blood mononuclear cells with recombinant interleukin 2 for 4 days were able to lyse normal PAM in a 4-h 51Cr release assay. Similarly, PAM recovered from patients suffering from nonneoplastic interstitial lung disorders, i.e., sarcoidosis and hypersensitivity pneumonitis, were shown to be susceptible to the cytotoxic function provided by LAK cells. Both autologous and allogeneic PAM were lysed by LAK cells, thus suggesting that the phenomenon we observed does not require a major histocompatibility complex restriction. Preincubation of PAM under study with γ-interferon did not affect their susceptibility to the lysis mediated by LAK cells. Furthermore, cold target inhibition assay demonstrated that normal PAM could efficiently compete with both NK-sensitive and NK-resistant target lines for the binding sites on LAK cells, thus indicating that the putative receptor(s), or at least the mechanism of target recognition, is shared by PAM and these different target cell lines. The evidence herein provided that LAK cells are cytotoxic to normal, nontransformed PAM points out that the pathogenetic mechanisms involving this self-addressed lytic activity could account for some adverse reactions related to LAK/interleukin 2 immunotherapy.

Original languageEnglish
Pages (from-to)1768-1773
Number of pages6
JournalCancer Research
Volume50
Issue number6
Publication statusPublished - 1990

Fingerprint

Lymphokine-Activated Killer Cells
Alveolar Macrophages
Interleukin-2
Extrinsic Allergic Alveolitis
Lymphokines
Sarcoidosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zambello, R., Trentin, L., Feruglio, C., Bulian, P., Masciarelli, M., Cipriani, A., ... Semenzato, G. (1990). Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells. Cancer Research, 50(6), 1768-1773.

Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells. / Zambello, R.; Trentin, L.; Feruglio, C.; Bulian, P.; Masciarelli, M.; Cipriani, A.; Agostini, C.; Semenzato, G.

In: Cancer Research, Vol. 50, No. 6, 1990, p. 1768-1773.

Research output: Contribution to journalArticle

Zambello, R, Trentin, L, Feruglio, C, Bulian, P, Masciarelli, M, Cipriani, A, Agostini, C & Semenzato, G 1990, 'Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells', Cancer Research, vol. 50, no. 6, pp. 1768-1773.
Zambello R, Trentin L, Feruglio C, Bulian P, Masciarelli M, Cipriani A et al. Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells. Cancer Research. 1990;50(6):1768-1773.
Zambello, R. ; Trentin, L. ; Feruglio, C. ; Bulian, P. ; Masciarelli, M. ; Cipriani, A. ; Agostini, C. ; Semenzato, G. / Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells. In: Cancer Research. 1990 ; Vol. 50, No. 6. pp. 1768-1773.
@article{4f9b3f1535c44c828bb4fb444e422b22,
title = "Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells",
abstract = "In this study we addressed the question of whether lymphokine-activated killer (LAK) cells, besides killing neoplastic cells, may exert a certain degree of lysis on the normal counterpart; in particular we took into consideration the toxicity against pulmonary alveolar macrophages (PAM). We demonstrated that human LAK cells generated in vitro following incubation of peripheral blood mononuclear cells with recombinant interleukin 2 for 4 days were able to lyse normal PAM in a 4-h 51Cr release assay. Similarly, PAM recovered from patients suffering from nonneoplastic interstitial lung disorders, i.e., sarcoidosis and hypersensitivity pneumonitis, were shown to be susceptible to the cytotoxic function provided by LAK cells. Both autologous and allogeneic PAM were lysed by LAK cells, thus suggesting that the phenomenon we observed does not require a major histocompatibility complex restriction. Preincubation of PAM under study with γ-interferon did not affect their susceptibility to the lysis mediated by LAK cells. Furthermore, cold target inhibition assay demonstrated that normal PAM could efficiently compete with both NK-sensitive and NK-resistant target lines for the binding sites on LAK cells, thus indicating that the putative receptor(s), or at least the mechanism of target recognition, is shared by PAM and these different target cell lines. The evidence herein provided that LAK cells are cytotoxic to normal, nontransformed PAM points out that the pathogenetic mechanisms involving this self-addressed lytic activity could account for some adverse reactions related to LAK/interleukin 2 immunotherapy.",
author = "R. Zambello and L. Trentin and C. Feruglio and P. Bulian and M. Masciarelli and A. Cipriani and C. Agostini and G. Semenzato",
year = "1990",
language = "English",
volume = "50",
pages = "1768--1773",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells

AU - Zambello, R.

AU - Trentin, L.

AU - Feruglio, C.

AU - Bulian, P.

AU - Masciarelli, M.

AU - Cipriani, A.

AU - Agostini, C.

AU - Semenzato, G.

PY - 1990

Y1 - 1990

N2 - In this study we addressed the question of whether lymphokine-activated killer (LAK) cells, besides killing neoplastic cells, may exert a certain degree of lysis on the normal counterpart; in particular we took into consideration the toxicity against pulmonary alveolar macrophages (PAM). We demonstrated that human LAK cells generated in vitro following incubation of peripheral blood mononuclear cells with recombinant interleukin 2 for 4 days were able to lyse normal PAM in a 4-h 51Cr release assay. Similarly, PAM recovered from patients suffering from nonneoplastic interstitial lung disorders, i.e., sarcoidosis and hypersensitivity pneumonitis, were shown to be susceptible to the cytotoxic function provided by LAK cells. Both autologous and allogeneic PAM were lysed by LAK cells, thus suggesting that the phenomenon we observed does not require a major histocompatibility complex restriction. Preincubation of PAM under study with γ-interferon did not affect their susceptibility to the lysis mediated by LAK cells. Furthermore, cold target inhibition assay demonstrated that normal PAM could efficiently compete with both NK-sensitive and NK-resistant target lines for the binding sites on LAK cells, thus indicating that the putative receptor(s), or at least the mechanism of target recognition, is shared by PAM and these different target cell lines. The evidence herein provided that LAK cells are cytotoxic to normal, nontransformed PAM points out that the pathogenetic mechanisms involving this self-addressed lytic activity could account for some adverse reactions related to LAK/interleukin 2 immunotherapy.

AB - In this study we addressed the question of whether lymphokine-activated killer (LAK) cells, besides killing neoplastic cells, may exert a certain degree of lysis on the normal counterpart; in particular we took into consideration the toxicity against pulmonary alveolar macrophages (PAM). We demonstrated that human LAK cells generated in vitro following incubation of peripheral blood mononuclear cells with recombinant interleukin 2 for 4 days were able to lyse normal PAM in a 4-h 51Cr release assay. Similarly, PAM recovered from patients suffering from nonneoplastic interstitial lung disorders, i.e., sarcoidosis and hypersensitivity pneumonitis, were shown to be susceptible to the cytotoxic function provided by LAK cells. Both autologous and allogeneic PAM were lysed by LAK cells, thus suggesting that the phenomenon we observed does not require a major histocompatibility complex restriction. Preincubation of PAM under study with γ-interferon did not affect their susceptibility to the lysis mediated by LAK cells. Furthermore, cold target inhibition assay demonstrated that normal PAM could efficiently compete with both NK-sensitive and NK-resistant target lines for the binding sites on LAK cells, thus indicating that the putative receptor(s), or at least the mechanism of target recognition, is shared by PAM and these different target cell lines. The evidence herein provided that LAK cells are cytotoxic to normal, nontransformed PAM points out that the pathogenetic mechanisms involving this self-addressed lytic activity could account for some adverse reactions related to LAK/interleukin 2 immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025350804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025350804&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 1768

EP - 1773

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -